{"id":"W4408206616","doi":"10.1007/s12325-025-03138-2","title":"A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Ustekinumab; Medicine; Psoriasis Area and Severity Index; Biosimilar; Randomized controlled trial; Internal medicine; Clinical endpoint; Adverse effect; Psoriasis; Dermatology; Infliximab; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005371229,0.0002899432,0.0006643372,0.0001395797,0.0001776501,0.00002434746,0.0005483155,0.0001495328,0.00004452173],"category_scores_gemma":[0.00006032979,0.0001367197,0.00007000412,0.00083917,0.0003560882,0.00009791143,0.0001465379,0.0004426346,0.000001550127],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000659921,"about_ca_system_score_gemma":0.0001034887,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001234331,"about_ca_topic_score_gemma":0.001066092,"domain_scores_codex":[0.9979854,0.0005669252,0.0005427911,0.0004523945,0.0001034379,0.0003490067],"domain_scores_gemma":[0.998498,0.0006562818,0.0001670578,0.000536644,0.0001156125,0.00002642761],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9703563,0.0004388565,0.01242177,0.0000164111,0.0002176407,7.687009e-7,0.0004028372,0.000818153,0.0003465099,0.0005695457,0.00003449021,0.01437667],"study_design_scores_gemma":[0.901688,0.002003192,0.05656448,0.0005160558,0.00009710499,0.000004360072,0.0003405991,0.00001847398,0.01772073,0.0003635493,0.02020427,0.0004792248],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9906574,0.003106064,0.0003202738,0.00140598,0.0002800145,0.003455286,0.0000580298,0.00001337948,0.000703612],"genre_scores_gemma":[0.9976778,0.0008288514,0.0004276824,0.0007843172,0.000009492265,0.0001149528,0.000008857792,0.00001349754,0.000134522],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06866839,"threshold_uncertainty_score":0.5575265,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02167875285679234,"score_gpt":0.3021284946839793,"score_spread":0.280449741827187,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}